פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר על ידו במרץ 4102.
|
|
- Brittany Richards
- 5 years ago
- Views:
Transcription
1 פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר על ידו במרץ SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF MEDICINAL PRODUCT Danol 200mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 200mg of danazol Also contains 76.6 mg of lactose monohydrate For a full list of excipients see PHARMACEUTICAL FORM Capsule 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Danol capsules are recommended for: Treatment of endometriosis amenable to hormonal management. Treatment of Hereditary angioedema. 4.2 Posology and Method of Administration Adults: Danol capsules should be given as a continuous course, dosage being adjusted according to the severity of the condition and the patient's response. A reduction in dosage once a satisfactory response has been achieved may prove possible. In fertile females, Danol capsules should be started during menstruation, preferably on the first day, to avoid exposing a pregnancy to its possible effects. Where doubt exists, appropriate checks should be made to exclude pregnancy before starting medication. Females of childbearing age should employ non-hormonal contraception throughout the course of treatment. In endometriosis the recommended dosage is 200mg to 800mg daily in a course of treatment lasting normally three to six months. Dosage should be increased if normal cyclical bleeding still persists after two months therapy, a higher dosage (not exceeding 800mg per day) may also be needed for severe disease. For the prophylaxis of hereditary angioedema the recommended initial dose is 200mg two or three times a day until the desired initial response is obtained; then the maintenance dosage is determined by decreasing the initial dosage by 50% or less at intervals of one to three months or longer, depending on frequency of attacks prior to treatment. Following a favourable response to Danol, the lowest effective maintenance dose should be sought for a continuous preventive treatment. Daily dosage may be increased by up to 200mg if condition is not controlled at lower doses. Elderly: Danol is not recommended. Children: Danol is not recommended. The capsules are for oral administration. 4.3 Contra-Indications 1
2 1. Pregnancy 2. Breast feeding 3. Markedly impaired hepatic, renal or cardiac function 4. Porphyria 5. Active thrombosis or thromboembolic disease and a history of such events 6. Androgen dependent tumour 7. Undiagnosed abnormal genital bleeding. 8. Hypersensitivity to danazol or to any of the excipients. 4.4 Special Warnings and Special Precautions for Use Special Warnings In the event of virilisation, Danol should be withdrawn. Androgenic reactions generally prove reversible, but continued use of Danol after evidence of androgenic virilisation increases the risk of irreversible androgenic effects. Danol should be stopped if any clinically significant adverse event arises, and particularly if there is evidence of papilloedema, headache, visual disturbances or other signs or symptoms of raised intracranial pressure, jaundice or other indication of significant hepatic disturbance, thrombosis or thromboembolism. Whilst a course of therapy may need to be repeated, care should be observed as no safety data are available in relation to repeated courses of treatment over time. The long-term risk of 17-alkylated steroids (including benign hepatic adenomata, peliosis hepatis and hepatic carcinoma), should be considered when danazol, which is chemically related to those compounds, is used. Data, from two case-control epidemiological studies, were pooled to examine the relationship between endometriosis, endometriosis treatments and ovarian cancer. These preliminary results suggest that the use of danazol might increase the baseline risk of ovarian cancer in - patients treated for endometriosis. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine. Precautions In view of its pharmacology, known interactions and side effects, particular care should be observed when using Danol in patients with hepatic or renal disease, hypertension or other cardiovascular disease and in any state which may be exacerbated by fluid retention as well as in diabetes mellitus, polycythaemia, epilepsy, lipoprotein disorder, and in those who have shown marked or persistent androgenic reaction to previous gonadal steroid therapy. Caution is advised in patients with migraine. Until more is known, caution is advised in the use of Danol in the presence of known or suspected malignant disease (see also contra-indications). Before treatment initiation, the presence of hormone dependent carcinoma should be excluded at least by careful clinical examination, as well as if breast nodules persist or enlarge during danazol treatment. In addition to clinical monitoring in all patients, appropriate laboratory monitoring should be considered which may include periodic measurement of hepatic function and haematological state. For long-term treatment (> 6 months) or repeated courses of treatment, biannual hepatic ultrasonography is recommended. Danazol should be initiated during menstruation. An effective, non-hormonal method of contraception should be employed (see Section 4.2 and 4.6 Pregnancy and Lactation). The lowest effective dose of Danol should always be sought. 4.5 Interactions with other medicinal products and other forms of Interaction 2
3 Anti-convulsant therapy: Danol may affect the plasma level of carbamazepine and possibly the patient's response to this agent and to phenytoin. With phenobarbitone it is likely that similar interaction would occur. Anti-diabetic therapy: Danol can cause insulin resistance. Oral anti-coagulant therapy: Danol can potentiate the action of warfarin. Anti-hypertensive therapy: Possibly through promotion of fluid retention, Danol can oppose the action of antihypertensive agents. Cyclosporin and tacrolimus: Danol can increase the plasma level of cyclosporin and tacrolimus, leading to an increase of the renal toxicity of these drugs. Concomitant steroids: Although specific instances have not been described, it is likely that interactions will occur between Danol and gonadal steroid therapy. Migraine therapy: Danol may itself provoke migraine and possibly reduce the effectiveness of medication to prevent that condition. Ethyl alcohol: Subjective intolerance in the form of nausea and shortness of breath has been reported. Alpha calcidol: Danol may increase the calcaemic response in primary hypoparathyroidism necessitating a reduction in dosage of this agent. Interactions with laboratory function tests: Danazol treatment may interfere with laboratory determination of testosterone or plasma proteins (See also section4.8 Undesirable effects) Statins: The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins metabolised by CYP3A 4 such as simvastatin, atorvastatin and lovastatin. 4.6 Fertility, pregnancy and lactation There is epidemiological and toxicological evidence of hazard in human pregnancy. Danazol is known to be associated with the risk of virilisation to the female foetus if administered during human pregnancy. Danazol should not be used during pregnancy. Women of childbearing age should be advised to use an effective, non-hormonal, method of contraception. If the patient conceives during therapy, danazol should be stopped. Danazol has the theoretical potential for androgenic effects in breast-fed infants and therefore either danazol therapy or breast-feeding should be discontinued. 4.7 Effects on Ability to Drive and Use Machines Danol has no or negligible influence on the ability to drive and use machines. 4.8 Undesirable Effects Blood and lymphatic system disorders Increase in red cell and platelet count. Reversible polycythaemia, leucopoenia, thrombocytopenia, eosinophilia and splenic peliosis. Endocrine disorders Androgenic effects: Acne, weight gain, increased appetite, seborrhoea, hirsutism, hair loss, voice change, which may take the form of hoarseness, sore throat or of instability or deepening of pitch. Hypertrophy of the clitoris, fluid retention. Other endocrine effects: Menstrual disturbances in the form of spotting, alteration of the timing of the cycle and amenorrhoea. Flushing, vaginal dryness, changes in libido, vaginal irritation and reduction in breast size. Modest reduction in spermatogenesis. Metabolism and nutrition disorders 3
4 Increased insulin resistance, increase in plasma glucagon, mild impairment of glucose tolerance. Increase in LDL cholesterol, decrease in HDL cholesterol, affecting all subfractions, and decrease in apolipoproteins AI and AII. Induction of aminolevulinic acid (ALA) synthetase, and reduction in thyroid binding globulin, T4, with increased uptake of T3 but without disturbance of thyroid stimulating hormone or free levothyroxine index. Psychiatric disorders Emotional lability, anxiety, depressed mood and nervousness. Nervous system disorders Dizziness, headache, vertigo, benign intracranial hypertension, migraine. Aggravation of epilepsy, carpal tunnel syndrome. Eye disorders Visual disturbances such as blurring of vision, difficulty in focusing, difficulty in wearing contact lenses and refraction disorders requiring correction. Respiratory, thoracic and mediastinal disorders Pleuritic pain, interstitial pneumonitis. Gastrointestinal disorders Nausea, epigastric pain. Cardiac disorders Hypertension, palpitations and tachycardia. Thrombotic events including sagittal sinus, cerebrovascular thrombosis as well as arterial thrombosis. Myocardial infarction. Hepatobiliary disorders Isolated increases in serum transaminase levels, cholestatic jaundice, benign hepatic adenomata and pancreatitis. Peliosis hepatitis as well as malignant hepatic tumour observed with long term use. Hepatocellular injury, hepatic failure, jaundices hepatocellular. Skin and subcutaneous tissue disorders Rashes, which may be maculopapular, petechial or purpuric and may be accompanied by fever or may take an urticarial form and may be accompanied by facial oedema. Sun-sensitive rash. Inflammatory erythematosus nodules, changes in skin pigmentation, exfoliative dermatitis and erythema multiforme. Musculoskeletal and connective tissue disorders Backache and muscle cramps which can be severe, with elevation of creatine phosphokinase levels. Muscle tremors, fasciculation, limb pain, joint pain and joint swelling. Renal and urinary disorders 4
5 Haematuria with prolonged use in patients with hereditary angioedema. General disorders and administration site conditions Fatigue Overdose Available evidence suggests that acute overdosage would be unlikely to give rise to immediate serious reaction. In the case of acute overdose, consideration should be given to reducing the absorption of the drug with activated charcoal and the patient should be kept under observation in case of any delayed reactions. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic Properties Pharmacotherapeutic group: sex hormones and modulators of the genital system, antigonadotropins and similar agents, ATC code: G03XA01. Danazol, 17a-pregna-2,4-dien-20-yno(2,3-d)-isoxazol-17-ol, is a synthetic steroid derived from ethisterone. Its pharmacological properties include: 1. Relatively marked affinity for androgen receptors, less marked affinity for progesterone receptors and least affinity for oestrogen receptors. Danazol is a weak androgen but in addition antiandrogenic, progestogenic, antiprogestogenic, oestrogenic and antioestrogenic actions have been observed. 2. Interference with the synthesis of gonadal steroids, possibly by inhibition of the enzymes of steroidogenesis, including 3 hydroxysteroid dehydrogenase,17 hydroxysteroid dehydrogenase, 17 hydroxylase, 17, 20 lyase, 11 hydroxylase, 21 hydroxylase and cholesterol side chain cleavage enzymes, or alternatively by inhibition of the cyclic AMP accumulation usually induced by gonadotrophic hormones in granulosa and luteal cells. 3. Inhibition of the mid-cycle surge of FSH and LH as well as alterations in the pulsatility of LH. Danazol can also reduce the mean plasma levels of these gonadotrophins after the menopause. 4. A wide range of actions on plasma proteins, including increasing prothrombin, plasminogen, antithrombin III, alpha-2 macroglobulin, C1 esterase inhibitor, and erythropoietin and reducing fibrinogen, thyroid binding and sex hormone binding globulins. Danazol increases the proportion and concentration of testosterone carried unbound in plasma. 5. The suppressive effects of danazol on the hypothalmic-pituitary-gonadal axis are reversible, cyclical activity reappearing normally within days after therapy. 5.2 Pharmacokinetic Properties Danazol is absorbed from the gastrointestinal tract, peak plasma concentrations of 50-80ng/ml being reached approximately 2-3 hours after dosing. Compared to the fasting state, the bioavailability has been shown to increase 3 fold when the drug is taken with a meal with a high fat content. It is thought that food stimulates bile flow which facilitates the dissolution and absorption of danazol, a highly lipophilic compound. The apparent plasma elimination half-life of danazol in a single dose is approximately 3-6 hours. With multiple doses this may increase to approximately 26 hours. None of the metabolites of danazol, which have been isolated, exhibits pituitary inhibiting activity comparable to that of danazol. Few data on excretion routes and rates exist. In the monkey 36% of a radioactive dose was recoverable in the urine and 48% in the faeces within 96 hours. 5.3 Preclinical Safety Data 5
6 There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC. 6. PHARMACEUTICAL PARTICULARS 6.1 List of Excipients Capsule Maize starch Lactose monohydrate Talc Magnesium stearate Capule Shell Gelatin Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172) Black Ink which contains: Shellac Glaze,Propylene glycol,black iron oxide, Ammonium hydroxide. OR Shellac, Dehydrated alcohol, Propylene glycol, Ammonia solution, Potassium hydroxide, Black iron oxide. OR Shellac glaze 45% (20% esterfied) in ethanol, black iron oxide (E172), propylene glycol, ammonium hydroxide 28%. OR Shellac, propylene glycol, strong ammonia solution, potassium hydroxide, black iron oxide (E 172). 6.2 Special Precautions for Storage Store in a dry place below 30 0 C. 7. MANUFACTURER Sanofi-Synthelabo Ltd Guildford Surrey GU1 4YS UK 8. LICENSE HOLDER Sanofi-aventis Israel ltd. POB 8090 Netanya
DANOGEN Capsules (Danazol)
Published on: 10 Jul 2014 DANOGEN Capsules (Danazol) Composition DANOGEN 50 Each capsule contains: Danazol 50 mg DANOGEN 100 Each capsule contains: Danazol 100 mg DANOGEN 200 Each capsule contains: Danazol
More informationPackage leaflet: Information for the patient. Danazol Capsules 100 mg Danazol Capsules 200 mg danazol
PACKAGE LEAFLET Package leaflet: Information for the patient Danazol Capsules 100 mg Danazol Capsules 200 mg danazol Read all of this leaflet carefully before you start taking this medicine because it
More informationPRODUCT INFORMATION PROVIRON
PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5
More informationCAS Registry No.:
Azol Danazol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Danazol Chemical name: 17α-pregna-2,4-dien-20-yno(2,3-d)isoxazol-17β-ol Structural formula: Molecular formula: C 22 H 27 NO 2 Molecular
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Finpros 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg finasteride. Excipient
More informationPROPECIA Tablets Merck Sharp & Dhome
PROPECIA Tablets Merck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT PROPECIA 1 mg Film-Coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet of Propecia contains 1 mg of finasteride
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Finasterid Actavis 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg finasteride.
More informationPRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl
PRODUCT INFORMATION SUSTANON '250' NAME OF THE MEDICINE Sustanon '250' ('250' mg/ml for injection): testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate.
More informationPackage Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)
Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains
More information4.2 Posology, method and duration of administration
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in May 2011. 1. NAME OF MEDICINAL PRODUCT Testoviron Depot Oily solution for injection
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride)
PACKAGE LEAFLET: INFORMATION FOR THE USER FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride) Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationDanazol apollo
Danazol apollo +9191 46 950 950 Danazol apollo +9191 46 950 950 Danazol CAS Number : 17230-88-5 Molecular Weight : 337.46 g/mol Molecular Formula : C22H27NO2 Systematic (IUPAC) : (1S,2R,13R,14S,17R,18S)-17-
More informationDr Tarza Jamal Pharmacology Lecture 2
Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More informationCinryze. Cinryze (C1 esterase inhibitor [human]) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.05 Subject: Cinryze Page: 1 of 5 Last Review Date: September 20, 2018 Cinryze Description Cinryze
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Finasteride 5mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5mg of finasteride. Excipient(s): Each tablet
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
AVODART SOFT CAPSULES 0.5 MG 1. NAME OF THE MEDICINAL PRODUCT Avodart 0.5 mg capsules, soft. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For excipients, see 6.1.
More informationDUPROST Capsules (Dutasteride)
Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride
More informationAntiduretic Hormone, Growth. Hormone & Anabolic Steroids
Goudarz Sadeghi, DVM, PhD, DSc Associate Professor of Pharmacology University of Tehran Faculty of Veterinary Medicine Veterinary Pharmacology Endocrine System Antiduretic Hormone, Growth Hormone & Anabolic
More informationPRODUCT MONOGRAPH. CYCLOMEN (danazol capsules, USP) 50mg, 100mg, 200mg Capsules. Pituitary Gonadotropin Inhibitor
PRODUCT MONOGRAPH Pr CYCLOMEN (danazol capsules, USP) 50mg, 100mg, 200mg Capsules Pituitary Gonadotropin Inhibitor sanofi-aventis Canada Inc. 2905 Place Louis-R.-Renaud Laval, Quebec H7V 0A3 Date of Revision:
More informationNEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 1 mg of finasteride.
1. PRODUCT NAME Profal, film coated tablets, 1 mg NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 1 mg of finasteride. Excipient of known effect: Lactose
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1 NAME OF THE MEDICINAL PRODUCT Lung test gas, CO/He AGA 0.28%, 9.3% medicinal gas, compressed
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lung test gas, CO/He AGA 0.28%, 9.3% medicinal gas, compressed 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Carbon monoxide (CO) 0.28% under
More information3. PHARMACEUTICAL FORM Capsules: dull yellow in colour, opaque, oblong soft gelatin capsules with GX CE2 printed on one side in red ink.
Avodart TM Dutasteride 1. NAME OF THE MEDICINAL PRODUCT AVODART* 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule for oral use contains 0.5 mg dutasteride. For excipients, see 6.1 List of Excepient.
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
AVODART SOFT CAPSULES 0.5 MG 1. NAME OF THE MEDICINAL PRODUCT AVODART 0.5 mg capsules, soft. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For excipients, see 6.1.
More informationAndriol Testocaps. NAME OF THE MEDICINE: Testosterone undecanoate DESCRIPTION PRODUCT INFORMATION
PRODUCT INFORMATION Andriol Testocaps NAME OF THE MEDICINE: Testosterone undecanoate Testosterone undecanoate, the active ingredient of Andriol Testocaps, is a white to creamy-white crystalline powder.
More informationDutasteride Avodart Softgel Capsule
Dutasteride Avodart Softgel Capsule PRODUCT DESCRIPTION Dutasteride (Avodart ) is available as dull yellow, opaque, oblong soft gelatin capsules containing a clear, colourless to slightly yellow liquid.
More informationNew Zealand Data Sheet
New Zealand Data Sheet 1. PRODUCT NAME TEROD 500 micrograms soft gelatin capsules. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 500 micrograms of dutasteride. For the full list of
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME DEPO-TESTOSTERONE 100mg/mL Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml solution for injection contains 100 mg/ml testosterone cypionate.
More informationUnderstanding combined oral contraception
Understanding combined oral contraception Paula Briggs, FFSRH Consultant in Community Sexual and Reproductive Health Southport and Ormskirk NHS Hospital Trust May Logan Centre, Bootle, L20 5DQ paulaeb@aol.com
More informationSUMMARY OF PRODUCT CHARACTERISTICS. AT: Finasterid Aurobindo 5 mg Filmtabletten BE: Finasteride Aurobindo Pharma 5 mg filmomhulde tabletten
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT AT: Finasterid Aurobindo 5 mg Filmtabletten BE: Finasteride Aurobindo Pharma 5 mg filmomhulde tabletten CY: Finasterid Aurobindo 5 mg
More informationXYOSTED (testosterone enanthate) injection, for subcutaneous use CIII Initial US approval: 1953 IMPORTANT SAFETY INFORMATION
ANTARES PHARMA ANNOUNCES THE COMMERCIAL AVAILABILITY OF XYOSTED (TESTOSTERONE ENANTHATE) INJECTION A NEW TREATMENT FOR ADULT MEN DIAGNOSED WITH TESTOSTERONE DEFICIENCY XYOSTED - A Novel Subcutaneous Testosterone
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Avodart 0.5 mg soft capsules. SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. Excipient with known
More informationVersion 4, 02/2016 SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET. common-spc Pg. 1
Version 4, 02/2016 SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 common-spc Pg. 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 common-spc Pg. 2 1. NAME OF THE MEDICINAL PRODUCT Testavan 20
More informationYour guide to. Danazol. (Danol ) Information and advice
Your guide to Danazol (Danol ) Information and advice Supporting patients and families affected by MPN MPN Voice previously known as MPD Voice Established by a group of MPN patients over 10 years ago,
More informationFINCAR Tablets (Finasteride)
Published on: 10 Jul 2014 FINCAR Tablets (Finasteride) Composition FINCAR Tablets Each film-coated tablet contains: Finasteride USP - 5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dutasteride 0.5 mg Capsules, Soft 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For the full list
More informationPanzyga Administration Guide
Immune Human Normal Globulin Immunoglobulin Intravenous (Human) (IVIg) Octapharma s new Intravenous Immunoglobulin (IVIG) Panzyga Administration Guide An educational service tool provided by Octapharma
More informationPRODUCT INFORMATION ANDROFORTE 5
PRODUCT INFORMATION ANDROFORTE 5 NAME OF THE MEDICINE Testosterone is an androgen. Chemically testosterone is 17β-hydroxyandrost-4-en-3-one and has the following structural formula: DESCRIPTION Chemical
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lung test gas, CO/C 2 H 2 /CH 4 AGA 0.3%, 0.3%, 0.3% medicinal gas, compressed 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Carbon monoxide
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Deratos 0.5 mg capsules, soft 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For the full list
More informationDEPO-Testosterone Injection is available in two strengths, 100 mg/ml and 200 mg/ml testosterone cypionate.
Depo -Testosterone testosterone cypionate injection, USP CIII DESCRIPTION DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate
More informationsocial impairment. The following exclusion criteria applied: age under 18 years; weight under 45 kg or over 80 kg;
Postgrad Med J (1991) 67, 450-454 The Fellowship of Postgraduate Medicine, 1991 Low dose danazol in the treatment of the premenstrual syndrome Miriam Deeny, Robert Hawthorn and D. McKay Hart Division ofobstetrics
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationNebido 1000mg/4ml, solution for injection
Nebido 1000mg/4ml, solution for injection Summary of Product Characteristics Updated 19-Oct-2018 Bayer plc 1. Name of the medicinal product Nebido 1000 mg/4 ml, solution for injection. 2. Qualitative and
More informationNatural estrogens estradiol estrone estriol
Estrogens Natural estrogens estradiol estrone estriol Nonsteroidal synthetic Diethylstilbestrol Chlorotrianisene Methallenestril Steroidal synthetic Ethinyl estradiol Mestranol Quinestrol To decrease some
More informationChapter 37 (pages ): Hereditary Angioedema and Bradykinin-Mediated Angioedema Prepared by: Sarah Spriet, DO
FIT Board Review Corner May 2017 Welcome to the FIT Board Review Corner, prepared by Tammy Peng, MD, and Amar Dixit, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the Board
More informationThis is an English translation of the original Chinese instruction leaflet generated by Google Translate. No amendments were made.
Approved Date: December 26, 2006 Revision Date: September 12, 2012 Modify Date: December 1, 2013 Finasteride tablets instructions Please read the instructions carefully and use under the guidance of a
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More information1. NAME OF THE MEDICINAL PRODUCT. Medicinal Air, Air Liquide 100%, medicinal gas, compressed. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Medicinal Air, Air Liquide 100%, medicinal gas, compressed. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Medicinal air 100% at a pressure of 200 bar (15 C). 3. PHARMACEUTICAL
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218
More informationTESTIM (testosterone gel) for topical use, CIII Initial U.S. Approval: 1953
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTIM safely and effectively. See full prescribing information for TESTIM. TESTIM (testosterone
More informationHGH for Sale Natural Anti-Aging Human Growth Hormone
HGH for Sale Natural Anti-Aging Human Growth Hormone Human growth hormone is one of the hottest supplement trends on the market, and now you can purchase top-quality HGH to be delivered right to your home!
More informationThe capsules are opaque, yellow, oblong soft gelatin capsules filled with an oily and yellowish liquid, without printing.
1. NAAM VAN HET GENEESMIDDEL Dutasteride 0,5 mg Teva, zachte capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg of dutasteride. Excipient with known effect: lecithin (may
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationLung Function medical gas mixture 1.
Medical Gas Data Sheet (MGDS) Lung Function medical gas mixture 1. Essential safety information. BOC: Living healthcare 02 Lung Function medical gas mixture 1 Lung Function medical gas mixture 1 03 Lung
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Medicinsk luft AGA 100%, medicinal gas, compressed. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Medicinal air 100% at a pressure of 200
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationPRODUCT INFORMATION REANDRON 1000
PRODUCT INFORMATION REANDRON 1000 NAME OF THE MEDICINE Reandron 1000 is a hormonal preparation that contains 1000 mg testosterone undecanoate. The chemical name for testosterone undecanoate is (17β)-17-[(1-Oxoundecyl)oxy]-androst-4-
More informationFinasteride 1mg film-coated tablets (Pharmacare )
Name of Medicine finasteride 1 mg tablet Presentation Brown colour, round, film-coated tablet, debossed with H on one side and 36 on the other side. Therapeutic Class Finasteride is a synthetic 4-azasteroid
More information1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride
1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride
More informationLung Function medical gas mixture 4.
Medical Gas Data Sheet (MGDS) Lung Function medical gas mixture 4. Essential safety information. BOC: Living healthcare 02 03 4.4 Special warnings and precautions for use is used for diagnostic and research
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Exembol Multidose 100 mg/ml concentrate for solution for infusion. Argatroban Monohydrate
PACKAGE LEAFLET: INFORMATION FOR THE USER Exembol Multidose 100 mg/ml concentrate for solution for infusion Argatroban Monohydrate Read all of this leaflet carefully before you start using this medicine.
More informationAUSTRALIAN PRODUCT INFORMATION PROPECIA (finasteride) Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION
AUSTRALIAN PRODUCT INFORMATION PROPECIA (finasteride) Tablets NAME OF THE MEDICINE Finasteride QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet of PROPECIA contains 1 mg of finasteride.
More informationMedical Gas Data Sheet (MGDS) Medical helium. BOC: Living healthcare
Medical Gas Data Sheet (MGDS) Medical helium BOC: Living healthcare 02 03 Summary of Product Characteristics (SPC) 4.6 Pregnancy and lactation 4.7 Effects on ability to drive and use machines Medical Helium
More informationWHY IS PREVENTION IMPORTANT?
A GUIDE TO TRUST THE POWER OF PREVENTION < 2 > WHY IS PREVENTION IMPORTANT? Hereditary angioedema (HAE) symptoms can range in severity. Some attacks may be mild or temporarily disabling, but others can
More informationNolvadex. Nolvadex Functions & Traits: Effects of Nolvadex:
Nolvadex Nolvadex is a popular and powerfully effective Selective Estrogen Receptor Modulator (SERM) that is often referred to as an anti-estrogen. However, while being an antagonist it is also an agonist
More informationCSL Behring PACKAGE LEAFLET: INFORMATION FOR THE USER
CSL Behring PACKAGE LEAFLET: INFORMATION FOR THE USER Berinert 500 IU Powder and solvent for solution for injection / infusion Berinert 1500 IU Powder and solvent for solution for injection Human C1-esterase
More informationFINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM
750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride
More informationNEW ZEALAND DATA SHEET FIRAZYR
NAME OF THE MEDICINE Icatibant acetate NEW ZEALAND DATA SHEET FIRAZYR Chemical Name of icatibant: D-Arginyl-L-arginyl-L-prolyl-L[(4R)-4-hydroxyprolyl]-glycyl- L[3-(2-thienyl)alanyl]-L-seryl-D-(1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl)-L[(3aS,7aS)-
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use testosterone gel safely and effectively. See full prescribing information for testosterone gel. Testosterone
More informationPRODUCT MONOGRAPH ANDROGEL. Testosterone gel. Androgens
PRODUCT MONOGRAPH ANDROGEL Testosterone gel 1% Androgens BGP Pharma ULC 85 Advance Road Etobicoke, Ontario M8Z 2S6 Date of Preparation: December 19, 2014 Date of Previous Revision: August 27, 2015 Date
More informationCLINICAL PHARMACOLOGY
OXANDROLONE- oxandrolone tablet American Health Packaging ---------- BOXED WARNINGS PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN
More informationSILOFAST D Capsules (Silodosin + Dutasteride)
Published on: 26 Sep 2016 SILOFAST D Capsules ( + ) Composition SILOFAST D 4 Capsules Each combipack contains: 10 hard gelatin capsules of and 10 soft gelatin capsules of (A) hard gelatin capsules Each
More informationTESTOSTERONE gel, for topical use, CIII Initial U.S. Approval: 1953
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTOSTERONE gel safely and effectively. See full prescribing information for TESTOSTERONE gel. TESTOSTERONE
More informationWhat do these athletes have in common?
What do these athletes have in common? Drugs in Sport Why do athletes cheat? 1988 Olympics 100m Final Why is this photo so iconic? 1988 Olympics 100m Final First time ever 4 of the 8 finalists run under
More informationCreatine Versus Anabolic Steroids. Over the past few years, many athletes have been using performance-enhancing
Hester 1 Kyle Hester Instructor s Name ENGL 1013 Date Creatine Versus Anabolic Steroids Over the past few years, many athletes have been using performance-enhancing supplements on a regular basis. Two
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Combodart 0.5 mg / 0.4 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 0.5 mg dutasteride and
More informationGynaecomastia. Benign breast conditions information provided by Breast Cancer Care
Gynaecomastia This booklet tells you about gynaecomastia. It explains what gynaecomastia is, what causes it, how it s diagnosed and what will happen if it needs to be treated or followed up. Benign breast
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationPRODUCT INFORMATION. PROPECIA (finasteride) Tablets NAME OF THE MEDICINE
WPC-MK0906-PPC-1T-022012 1 PRODUCT INFORMATION PROPECIA (finasteride) Tablets NAME OF THE MEDICINE Finasteride is described chemically as: N-(1,1-dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17βcarboxamide.
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication o 50 mg/0.5 ml. Revised: 09/2018 o 100 mg/0.5 ml
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XYOSTED safely and effectively. See full prescribing information for XYOSTED. XYOSTED (testosterone
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationPROPECIA finasteride 1 mg tablet
Name of Medicine PROPECIA finasteride 1 mg tablet Presentation A tan octagonal convex tablet embossed with a P logo on one side and PROPECIA on the other. Diameter: 7.14 mm. Therapeutic Class PROPECIA
More informationCLINICAL PHARMACOLOGY
TESTOPEL- testosterone pellet Slate Pharma ---------- DESCRIPTION TESTOPEL Pellets (testosterone) are cylindrically shaped pellets 3.2mm (1/8 inch) in diameter and approximately 9mm in length. Each sterile
More information1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING
SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier ZOLADEX FOR DEPOT/IMPLANT Details of the supplier of the safety data sheet : ASTRAZENECA PTY
More informationRECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS. Hereditary Angioedema
RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS Hereditary Angioedema TRUST PROVEN PREVENTION WITH CINRYZE Whether your patients are new to treatment or are continuing their
More informationPRODUCT INFORMATION. PROPECIA (finasteride) Tablets NAME OF THE MEDICINE
PRODUCT INFORMATION PROPECIA (finasteride) Tablets NAME OF THE MEDICINE Finasteride is described chemically as: N-(1,1-dimethylethyl)-3-oxo-4-aza-5 -androst-1-ene-17 carboxamide. The CAS No is 98319-26-7.
More informationANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Ruconest 2100 U powder for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 2100 units
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationPRODUCT INFORMATION. Apo-Finasteride 1 (Finasteride Film-coated Tablets 1 mg)
NAME OF THE MEDICINE PRODUCT INFORMATION Apo-Finasteride 1 (Finasteride Film-coated Tablets 1 mg) Finasteride is described chemically as: N-(1,1-dimethylethyl)-3-oxo-4-aza-5 -androst-1-ene- 17 carboxamide.
More information